{"url_path":"/sec/fulc/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-178814-index.html","accession_number":"0001193125-26-178814","cik":"0001680581","ticker":"FULC","issuer_name":"Fulcrum Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-178814-index.html","primary_entity_key":"0001680581","primary_entity_name":"Fulcrum Therapeutics, Inc."},"word_count":169,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n(a) None.\n\n(b) None.\n\n(c) Director and Officer Trading Plans and Arrangements\n\n65\n\n \n\nOn March 27, 2026, Alan Ezekowitz, a member of our board of directors, terminated a Rule 10b5-1 trading arrangement he had previously adopted on December 29, 2025 with respect to the sale of up to 124,713 shares of our common stock. The trading plan was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and was expected to remain in effect until December 31, 2026. As of the date of termination, Dr. Ezekowtiz had not sold any common shares under the terms of such trading plan. On March 27, 2026, Dr. Ezekowtiz adopted a trading plan for the potential exercise of vested stock options and the associated sale of up to 42,000 shares of our common stock. The trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is expected to remain in effect until April 1, 2027.\n\n \n\n66"}